Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma

Journal of Hepatology

Volumn 59, Issue 6, 2013, Pages 1193-1199

  Rodríguez Perálvarez, Manuel ^a   Tsochatzis, Emmanuel ^b   Naveas, María Carmen ^a   Pieri, Giulia ^b   García Caparrós, Carmen ^a   O'Beirne, James ^b   Poyato González, Antonio ^a   Ferrín Sánchez, Gustavo ^a   Montero Álvarez, Jose Luis ^a   Patch, David ^b   Thorburn, Douglas ^b   Briceño, Javier ^a   De La Mata, Manuel ^a   Burroughs, Andrew Kenneth ^b  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Calcineurin inhibitors; Hepatocellular carcinoma; Immunosuppression; Liver transplantation; Recurrence; Trough concentrations

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; DEFLAZACORT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; TACROLIMUS;

ADULT; ARTICLE; CANCER RISK; DEMOGRAPHY; DRUG EXPOSURE; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE;

CALCINEURIN INHIBITORS; CNI; HCC; HEPATOCELLULAR CARCINOMA; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; LT; RECURRENCE; TC; TROUGH CONCENTRATIONS;

AGED; CALCINEURIN; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TOR SERINE-THREONINE KINASES;

EID: 84888013803     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.07.012     Document Type: Article

References (25)

1. J. Bruix, and M. Sherman Management of hepatocellular carcinoma Hepatology 42 2005 1208 1236
2. M.W. Welker, W.O. Bechstein, S. Zeuzem, and J. Trojan Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge Transpl Int 26 2013 109 118
3. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
4. M. Maluccio, V. Sharma, M. Lagman, S. Vyas, H. Yang, and B. Li Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression Transplantation 76 2003 597 602
5. T. Ogawa, H. Tashiro, Y. Miyata, Y. Ushitora, Y. Fudaba, and T. Kobayashi Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model Am J Transplant 7 2007 347 355
6. M. Vivarelli, A. Cucchetti, F. Piscaglia, G. La Barba, L. Bolondi, and A. Cavallari Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression Liver Transpl 11 2005 497 503
7. M. Vivarelli, A. Cucchetti, G. La Barba, M. Ravaioli, M. Del Gaudio, and A. Lauro Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence Ann Surg 248 2008 857 862
8. M. Rodriguez-Peralvarez, G. Germani, V. Papastergiou, E. Tsochatzis, E. Thalassinos, and T.V. Luong Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long term outcome J Hepatol 58 2013 262 270
9. M. Rodriguez-Peralvarez, G. Germani, T. Darius, J. Lerut, E. Tsochatzis, and A.K. Burroughs Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis Am J Transplant 12 2012 2797 2814
10. A.O. Ojo, P.J. Held, F.K. Port, R.A. Wolfe, A.B. Leichtman, and E.W. Young Chronic renal failure after transplantation of a nonrenal organ N Engl J Med 349 2003 931 940
11. H.A. Edmonson, and P.E. Steiner Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies Cancer 7 1954 462 503
12. M. Rodriguez-Peralvarez, T.V. Luong, L. Andreana, T. Meyer, A.P. Dhillon, and A.K. Burroughs A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability Ann Surg Oncol 20 2013 325 339
13. V. Mazzaferro, J.M. Llovet, R. Miceli, S. Bhoori, M. Schiavo, and L. Mariani Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis Lancet Oncol 10 2009 35 43
14. A. Quaglia, N. Etessami, R. Sim, J. Difford, and A.P. Dhillon Vascular invasion and herniation by hepatocellular carcinoma in cirrhosis: a wolf in sheep's clothing? Arch Pathol Lab Med 129 2005 639 644
15. V.C. McAlister, E. Haddad, E. Renouf, R.A. Malthaner, M.S. Kjaer, and L.L. Gluud Cyclosporin vs. tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis Am J Transplant 6 2006 1578 1585
16. M. Rodríguez-Perálvarez, G. Germani, T. Darius, J. Lerut, E. Tsochatzis, and M. De la Mata Tacrolimus exposure after liver transplantation in randomized controlled trials: too much for too long Am J Transplant 13 2013 1371 1372
17. M. Rodriguez-Peralvarez, G. Germani, T. Darius, J. Lerut, E. Tsochatzis, and A.K. Burroughs Reducing early exposure to calcineurin inhibitors: the key factor for a successful renal sparing strategy Am J Transplant 13 2013 239
18. P. De Simone, F. Nevens, L. De Carlis, H.J. Metselaar, S. Beckebaum, and F. Saliba Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial Am J Transplant 12 2012 3008 3020
19. L. Fischer, J. Klempnauer, S. Beckebaum, H.J. Metselaar, P. Neuhaus, and P. Schemmer A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation-PROTECT Am J Transplant 12 2012 1855 1865
20. C. Toso, S. Merani, D.L. Bigam, A.M. Shapiro, and N.M. Kneteman Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma Hepatology 51 2010 1237 1243
21. G. Schumacher, M. Oidtmann, A. Rueggeberg, D. Jacob, S. Jonas, and J.M. Langrehr Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth World J Gastroenterol 11 2005 1420 1425
22. O. Massoud, and R.H. Wiesner The use of sirolimus should be restricted in liver transplantation J Hepatol 56 2012 288 290
23. K.V. Menon, A.R. Hakeem, and N.D. Heaton Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma Aliment Pharmacol Ther 37 2013 411 419
24. W. Liang, D. Wang, X. Ling, A.A. Kao, Y. Kong, and Y. Shang Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis Liver Transpl 18 2012 62 69
25. C. Duvoux, F. Roudot-Thoraval, T. Decaens, F. Pessione, H. Badran, and T. Piardi Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of milan criteria Gastroenterology 143 2012 986 994